GlassScriptPhysician profile
Carrie Peterson
NPI 1881055291
$3,271.95
in general payments reported to CMS, 2019-2025
26 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $990 · 2023: $304 · 2024: $436 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,415 · Education: $86.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,414.94 |
| Education | $86.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $355.62 | 2021-2022 | |
| Abbvie INC. | $319.19 | 2023-2024 | |
| Glaxosmithkline, LLC. | $267.25 | 2021-2025 | Ojjaara |
| Kite Pharma, INC. | $264.23 | 2022-2025 | Yescarta |
| Genmab U.S., INC. | $236.33 | 2023-2025 | Epkinly |
| Blueprint Medicines Corporation | $224.42 | 2022-2024 | Ayvakit |
| Gilead Sciences, INC. | $209.81 | 2021 | |
| Janssen Biotech, INC. | $177.35 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $145.90 | 2021-2024 | |
| Lilly USA, LLC | $128.48 | 2022 | |
| Sobi, INC | $125.00 | 2022 | |
| Myovant Sciences INC. | $114.40 | 2021 | |
| Incyte Corporation | $113.89 | 2025 | Niktimvo |
| Jazz Pharmaceuticals INC. | $102.72 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $99.50 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $91.43 | 2025 | Xpovio |
| Janssen Scientific Affairs, LLC | $64.83 | 2022 | |
| Celgene Corporation | $42.30 | 2025 | Abecma, Breyanzi |
| Daiichi Sankyo INC. | $37.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.49 | 2024 | Fruzaqla |
| Tempus Ai, INC | $26.33 | 2024 | |
| Pfizer INC. | $25.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.88 | 2022 | |
| Tersera Therapeutics LLC | $19.36 | 2021 | |
| Urogen Pharma, INC. | $13.40 | 2023 | Jelmyto |
| Amgen INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.